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Abstract
Background: The airway epithelial cell plays a central role in coordinating the pulmonary response to injury and
inflammation. Here, transforming growth factor-β (TGFβ) activates gene expression programs to induce stem cell-like
properties, inhibit expression of differentiated epithelial adhesion proteins and express mesenchymal contractile
proteins. This process is known as epithelial mesenchymal transition (EMT); although much is known about the
role of EMT in cellular metastasis in an oncogene-transformed cell, less is known about Type II EMT, that occurring in
normal epithelial cells. In this study, we applied next generation sequencing (RNA-Seq) in primary human airway
epithelial cells to understand the gene program controlling Type II EMT and how cytokine-induced inflammation
modifies it.
Results: Generalized linear modeling was performed on a two-factor RNA-Seq experiment of 6 treatments of telomerase
immortalized human small airway epithelial cells (3 replicates). Using a stringent cut-off, we identified 3,478 differentially
expressed genes (DEGs) in response to EMT. Unbiased transcription factor enrichment analysis identified three clusters of
EMT regulators, one including SMADs/TP63 and another NF-κB/RelA. Surprisingly, we also observed 527 of the EMT DEGs
were also regulated by the TNF-NF-κB/RelA pathway. This Type II EMT program was compared to Type III EMT in TGFβ
stimulated A549 alveolar lung cancer cells, revealing significant functional differences. Moreover, we observe that Type II
EMT modifies the outcome of the TNF program, reducing IFN signaling and enhancing integrin signaling. We confirmed
experimentally that TGFβ-induced the NF-κB/RelA pathway by observing a 2-fold change in NF-κB/RelA nuclear
translocation. A small molecule IKK inhibitor blocked TGFβ-induced core transcription factor (SNAIL1, ZEB1 and
Twist1) and mesenchymal gene (FN1 and VIM) expression.
Conclusions: These data indicate that NF-κB/RelA controls a SMAD-independent gene network whose regulation is
required for initiation of Type II EMT. Type II EMT dramatically affects the induction and kinetics of TNF-dependent
gene networks.
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Background
The airway mucosa consists of highly polarized, differenti-
ated epithelial cell types, whose primary role is to restrict
fluid loss and limit inhaled particulate access to the in-
ternal milieu [1]. Exposure to aero-allergens, respiratory
viruses or reactive oxygen stress, induces anchorage-
dependent cell death (anoikis). During the process of
anoikis, epithelial sloughing and disruption of the base-
ment membrane releases sequestered extracellular
matrix-associated epithelial growth factors, transform-
ing growth factor (TGF), epidermal growth factor
(EGF) and fibroblast growth factor (FGF). These epi-
thelial growth factors activate gene expression pro-
grams in resident stem cell population (basal cells) to
initiate epithelial repair and regeneration.
TGFβ-stimulation of normal epithelial cells activates a
de-differentiation program to promote cellular regeneration
and extracellular matrix formation [1–3], referred to as
Type II epithelial mesenchymal transition (EMT; [4]). Type
II EMT induces loss of apical-basal polarity through cyto-
skeletal reorganization and dissolution of tight junctions.
Concomitantly the cells express mesenchymal smooth
muscle cell actin and intermediate filament vimentin (VIM)
enhancing motility, and secrete collagen (Col1A), fibro-
nectin (FN1), and matrix metalloproteinases (MMPs)
promoting extracellular matrix deposition. Collectively
this response promotes airway remodeling with expan-
sion of the smooth muscle cell layer, repair of the epi-
thelial surface and fibrosis [4, 5]. In this way, the airway
epithelium plays a primary role in the resolution of -
injury or, if unresolved, the pathogenesis of chronic
airway disease [6].
EMT is a dynamic and reversible epigenetic reprogram-
ming event that plays a role in embryogenesis, organ
homeostasis in response to acute injury, or cancer progres-
sion/metastasis, referred to as Types I, II, or III EMT, re-
spectively [4]. Using Type III EMT as a model of cancer
progression and metastases, the molecular signaling of how
TGFβ1 initiates EMT has been studied extensively. Ligand
induced activation of the transmembrane serine/threonine
kinase TGFβ receptor type II (TGFβRII) recruits and phos-
phorylates TGFβRI to signal through Smad-dependent,
“canonical” and Smad-independent “noncanonical” path-
ways [7]. In the canonical pathway, phosphorylated Smad2/
3 binds to Smad4 and the complex then translocates to the
nucleus. The noncanonical signaling pathways involve
downstream PI3K/Akt, Ras small GTPases, Wnt/β-catenin,
ERK, p38, and JNK. Collectively, the canonical and nonca-
nonical pathways converge on a core set of transcription
factors that function to initiate and maintain EMT: SNAIL
(SNAI) 1/2, zinc finger E-box binding (ZEB) 1/2, Twist 1/2,
Goosecoid and others [8].
The core EMT transcription factors mediate a coordi-
nated series of gene activation/repression and chromatin
reprogramming events to shift cells to the mesenchymal
phenotype. The activated Smad 2/3/4 trimer binds to
Smad-binding elements in the regulatory regions of
SNAIL, JunB and c-Jun, activating their expression by
recruiting coactivators including the cAMP-response
element binding protein (CBP)/p300 histone acetyltrans-
ferases [9]. SNAIL, in turn, represses ECad and zona
occludin-1 genes by recruiting the polycomb complex,
producing silencing histone modifications [10–12]. Smad
signaling also increases expression of ZEB1/2, resulting
in MMP and collagen 1A expression [8]. ZEB interacts
with lysine-specific demethylase (LSD1), a protein in-
volved in histone demethylation and chromatin repro-
gramming in EMT [13, 14]. Together these proteins
coordinate both the repression of epithelial related genes
and activation of mesenchymal genes.
Because of the temporal interplay of diverse signaling
programs required to initiate and maintain EMT repro-
gramming, the EMT is highly modified by the state of
cellular transformation and concomitant activation of
extracellular signaling pathways. Oncogenic mutations
in K-ras, activation of Wnt signaling, ROS stress and
activation of insulin-like growth factor pathways that
cross-talk with the TGFβ pathway modify the expres-
sion of the EMT program [15]. As a result, the EMT
program can be modulated by extracellular matrix in-
teractions [16], and, of interest here, pro-inflammatory
monocyte derived cytokines. TNF is a prototypical
monokine [16, 17], whose actions trigger activation of
p38 MAPK and JNK, essential components of the non-
canonical TGFβ signaling pathways [18, 19], and induce
EMT in K-ras transformed epithelial cells through the
actions of NF-κB on the Twist EMT core transcription
factor [16, 20]. However, the role of NF-κB signaling in
the EMT of normal epithelial cells is not known.
In this study we sought to examine the gene program
of Type II EMT and to identify how this process was
modulated by interaction with the innate signaling path-
way. A well-established model of TGFβ-induced EMT
was applied to primary immortalized human small air-
way epithelial cells (hSAECs) to identify the gene expres-
sion networks responsible [5], and understand how
activation of the innate response was modulated by
EMT. Surprisingly, we observed that TGFβ produced a
gene expression program that was significantly enriched
in NF-κB-dependent genes identified by comparison to
TNF dependent genes and to RelA enriched target genes
in public ChIP-Seq data. Moreover, Type II EMT produces
profound rewiring of the TNF gene program, skewing
the pathway towards expression of integrin signaling
to maintain the EMT state. We demonstrate that inhi-
biting NF-κB/RelA via gene silencing or by inhibition
of the IKK regulatory kinase blocked TGFβ-induced
EMT. These data indicate that NF-κB/RelA gene
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expression program is a major regulator of TGFβ-induced
Type II EMT.
Methods
hSAEC culture and EMT transformation
An immortalized human small airway epithelial cell
(hSAEC) line was established by infecting primary
hSAECs with human telomerase (hTERT) and cyclin
dependent kinase (CDK)-4 retrovirus constructs [21]. The
immortalized hSAECs were grown in SAGM small airway
epithelial cell growth medium (Lonza, Walkersville, MD)
in a humidified atmosphere of 5 % CO2. For induction
of EMT, hSAECs were TGFβ stimulated for 15 days
(10 ng/ml, PeproTech, Rocky Hill, NJ). The small mol-
ecule inhibitor of IKK, BMS345541 was purchased
from Sigma Aldrich and used at 10 μM [22].
Fluorescence microscopy
hSAECs were incubated in the absence or presence of
TGFβ (10 ng/mL) for 15 days, re-plated on glass cover
slips pretreated with rat tail collagen (Roche Applied
Sciences) and fixed with 4 % paraformaldehyde in PBS.
Afterwards, the fixed cells were stained with Alexa
Fluor® 568 phalloidin for cytoplasmic distribution of
F-actin (shown in red color) and also counterstained
with 4’, 6-diamidino-2-phenylindole (DAPI) for nuclear
staining (shown in blue color). The cells were visualized
with a Nikon fluorescence confocal microscope at a
magnification of 63× [5, 23].
Quantitative real time PCR (Q-RT-PCR)
Reverse transcription was performed on 1 μg of total
RNA with random primers, utilizing SuperScript III
first-strand synthesis system for RT-PCR (Life technolo-
gies, Invitrogen) under conditions recommended by the
manufacturer. Equivalent amounts of RNA were assayed
by quanitative (Q) Q-PCR. The PCR reaction consisted
of SYBR Green® PCR Master Mix (Bio-Rad), template
cDNA and assay primers (Table 1) in a total reaction
volume of 20 μl. Thermal cycling (50 °C, 2 min; 95 °C,
10 min; and 40 cycles at 95 °C, 15 S; 60 °C, 1 min) was
performed using a MyiQ Single Color Real-Time PCR
Detection System (Bio-Rad). Threshold cycle numbers
(Ct) were defined as fluorescence values, generated by
SYBR green binding to double stranded PCR products,
exceeding baseline. Relative transcript levels were quan-
tified as a comparison of measured Ct values for each re-
action [24], normalized using cyclophilin as an internal
control.
RNA extraction and qualification
Total cellular RNA was extracted using either RNAqueous™
phenol-free total RNA isolation kits (Life Technologies,
CA) or Quick-RNA MiniPrep kits (ZYMO Research)
according to the manufacture’s recommendations. RNA
was quantified spectrophotometrically using a NanoDrop
ND-1000 (NanoDrop Technologies, DE). Quality of the
purified RNA was assessed by visualization of 18S and 28S
RNA bands using an Agilent BioAnalyzer 2100 (Agilent
Technologies, CA). The resulting electropherograms were
used in the calculation of the 28S/18S ratio and the RNA
Integrity Number.
Library construction and sequencing
Poly-A+ RNA was selected from total RNA (1 μg) using
oligo dT-attached magnetic beads. Bound RNA was frag-
mented by incubation at 94 °C for eight (8) minutes in
19.5 μl of fragmentation buffer (Illumina). First and sec-
ond strand synthesis, adapter ligation and amplification
of the library were performed using the Illumina TruSeq
Table 1 PCR Primers for genes in Q-RT-PCR analysis
Sequence (5’- 3’)
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RNA Sample Preparation kit under conditions pre-
scribed by the manufacturer (Illumina). Samples were
tracked using “index tags” incorporated into the
adapters. Library quality was evaluated using an Agilent
DNA-1000 chip on an Agilent 2100 Bioanalyzer. Quanti-
fication of library DNA templates was performed using
qPCR and a known-size reference standard. Cluster for-
mation of the library DNA templates was performed
using the TruSeq PE Cluster Kit v3 (Illumina) and the
Illumina cBot workstation using conditions recom-
mended by the manufacturer. Template input was ad-
justed to obtain a cluster density of 700–900 K/mm2.
Paired end 50 base sequencing by synthesis was per-
formed using TruSeq SBS kit v3 (Illumina) on an Illumina
HiSeq 1000 using protocols defined by the manufacturer.
GLM modeling and pathway analysis
As shown in Table 2, the experimental design has six
sample groups and requires a two factor analysis for
time of TNF stimulation (“Time”) and presence of TGFβ
stimulation (“Transformed”). For this purpose we
employed the Generalized Linear Modeling (GLM) cap-
abilities in the R Bioconductor package edgeR [25] to
perform the data modeling phase of the analysis within
our data analysis pipeline shown in Fig. 2b. EdgeR was
developed to analyze differential count data arising from
designed experiments such as RNA-Seq with single and
multiple experimental factors and small numbers of rep-
licates (here n = 3). It includes important statistical
methods such as scaled normalization using trimmed
means, the negative binomial distribution to describe
read count variability, estimates of gene specific disper-
sion parameters by conditional maximum likelihood
using Empirical Bayes methods, exact tests for differen-
tial gene expression analysis (DEGA) of one factor ex-
perimental designs and GLM for DEGA on multiple
factor designs.
The raw NGS analysis passed eleven separate quality
analyses by FastQC [26]. Reads were aligned using
TopHat2 [27], a fast splice junction mapper that aligns
RNA-Seq reads using the ultra-high-throughput short
read aligner Bowtie2 [28], using the Burrows-Wheeler
index method. The alignment across all 18 samples
produced a mean Overall Read Alignment Rate of 96.4
± 0.4 % and a mean Concordant Pair Alignment Rate of
88.0 ± 0.2 %, confirming that the read alignment was ex-
cellent and that data was of high quality. (The results of
QA/QC of RNA Seq are provided at Additional file 1).
As shown in Fig. 2b, edgeR used the resulting RNA-Seq
read count data to build the counts table in edgeR to begin
DGEA. Our experimental design has six groups of cell types
(Table 2) each comprised of three samples, thereby giving a
total of 18 sample columns with 23,710 rows of read counts,
each row representing a unique gene in the count table.
Data filtering by removing unresponsive (i.e., unin-
formative) genes, was performed to improve the power
of the study by reducing effects of multiple testing cor-
rection. We use this step to eliminate seemingly unre-
sponsive genes (rows) from the count table using our
rule that to be considered responsive, at least one of the
six groups has to have a significant number of counts in
at least two of its three samples. This filtering step culled
out 7,346 rows resulting in a final read count table having
16,364 genes with a mean library size of 4.54E^07 across
the 18 samples. This reduced read count table resulted in a
mean scaling factor of 1.002 (range: 0.7985 – 1.0990).
Before creating a model design, we identified the
model factors (Transformed. Time) and levels to edgeR
as [N.0 h, N.1 h, N.12 h, Y.0 h, Y.1 h, Y.12 h] where N = no
TGFβ transformation, Y = transformation with TGFβ and
hr = time post TNFα treatment in hours. From these fac-
tors and levels we can identify the important contrasts that
we would like to explore in our DEGA as shown in Table 3.
We then designed the statistical model that was most ap-
propriate for guiding the analysis in edgeR. This approach
allowed us to optimize the information content while min-
imizing type I and type II errors, so we can then select
those genes most suitable for pathways analysis.
The edgeR GLMs are non-linear models requiring it-
erative fitting and dispersion estimation to allow it to
account for variations in gene abundance between RNA
samples. EdgeR uses the Cox-Reid profile-adjusted
Table 2 Abbreviations and descriptions of the sample groups
for differential gene expression (DGE) analysis
Code Description
CE Control (C) untransformed Epithelial cells (E)
CM Control (C) TGFβ transformed Mesenchymal cells (M)
T1E TNFα treated (T) E cells 1 h post treatment
T1M TNFα treated (T) M cells 1 h post treatment
T12E TNFα treated (T) E cells 12 h post treatment
T12M TNFα treated (T) M cells 12 h post treatment
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likelihood method in estimating dispersions and the
read count data is modeled using the negative binomial
distribution because it accounts for overdispersion,
which the Poisson model does not. This is important in
RNA-Seq experiments because the observed variance
(i.e., dispersion) in the read count data is often greater
than that predicted from statistical theory. The tagwise
dispersion was estimated in a gene-wise fashion in three
steps using empirical Bayes shrinkage via a weighted
likelihood method. Our estimated common dispersion
was 0.01548079 which suggests that our sequencing
quality is very good.
We next performed the GLM fit using the statistical
design then performed the GLM Likelihood Ratio Test
(LRT) for each of the contrasts in Table 3. Using each of
the LRT outputs, we then performed Bonferroni FWER
[29] and Benjamini and Hochberg FDR [30] multiple
testing corrections on the DGE for each contrast using
the edgeR topTags method. For further analysis such as
pathway analysis, gene selection stringency is a key issue
so we used a 2× absolute fold change cutoff before
p-value filtering. This was a very strong response field
and was amenable to a very high level of stringency so
we focused on the Bonferonni corrected results with a
FWER p-value cutoff of 0.00001 to insure that genes
chosen for further analysis were reliably responsive to
our experimental conditions and to keep the number of
genes in the downstream analytical pool reasonable.
Differentially expressed genes are shown in Additional
files 2, 3, 4, 5, 6, 7, 8, and 9.
Venn diagrams were created to examine the intersec-
tions and relative complements of groups of contrasts
(treatment pairs compared) that were deemed biologically
interesting using locally developed tools. Subsets of genes
identified as interesting were explored using QIAGEN’s In-
genuity® Pathways Analysis suite (IPA®, QIAGEN Redwood
City, www.qiagen.com/ingenuity) for pathways, networks,
and functional analyses.
Transcription factor enrichment analysis
ChIP-X data were downloaded from the website http://
amp.pharm.mssm.edu/lib/chea.jsp in April 2014. The
ChIP-X data consist of 148 transcription factors (TFs)
and their respective target genes (TGs) derived from
ChIP-chip, ChIP-Seq, ChIP-PET or DamID experiments
in 237 publications [31]. Since TFs in different cell lines
and treatments may result in different TF binding data,
we separated experiments on the same TF, resulting in
345 combinations of TF and experiments performed on
human, mouse and rat cells. Among the 345 TF binding
experiments, 148 were performed on human. Here we
refer to the ChIP-X data as the ChEA ChIP-X data set.
We also downloaded the uniform histone and TF binding
peaks from the Encyclopedia of DNA Elements (ENCODE)
Consortium website (http://ftp.ebi.ac.uk/pub/databases/
ensembl/encode/integration_data_jan2011/byDataType/
signal/jan2011/bigwig/) to serve as a second data set. As
described above, we separated binding peaks of the same
TF from different experiments, which results in 1,169 dis-
tinct ChIP-Seq experiments. The target genes correspond-
ing to the TF binding peaks were identified according to
PAVIS criteria by using our own scripts [32]. Here the coor-
dinates of the peaks were mapped based on the hg19
refFlat.txt file downloaded from UCSC on Feb. 2012.
Differentially expressed genes (DEGs) between epithelial
cells and mesenchymal cells were identified with FPKM
fold change ratio > = 2 or < =− 2 and q-value < =0.01 from
the RNA-Seq data. 3,487 differentially expressed genes were
identified among the 23,284 genome-wide genes consid-
ered. Among the DEGs, 2010 genes are downregulated and
1477 are upregulated.
To determine if the transcriptional program regulated
by a specific transcription factor from the above 148
transcription factors was activated in the EMT process
or not, the hypergeometric probability distribution was
used as the background distribution. The enrichment for
each transcription factor regulated target gene (TG) was
calculated by p-value = 1-hygecdf (k-1, N, K, n) using the
Matlab build-in function hygecdf. The number of over-
lapping genes between the DEGs and the target genes
for the specific transcription factor is k; N is the number
of genome-wide genes: 23,284; K, the number of the
TGs of the TF in the ChIP-data; n, the number of DEGs.
For multiple testing corrections, Bonferroni FWER was
then performed by multiplying the p-value with the
number of TF binding experiments, i.e., 345 TF and
experimental combinations used in the analysis based
on the ChEA ChIP-X data and 1,169 that based on
ENCODE ChIP-Seq data as the corrected p-value. Enrich-
ment fold ratio was calculated by k/n/(K/N). If the cor-
rected p-value by Bonferroni correction was smaller than
0.01 and fold ratio is greater than 1.5, the corresponding
transcription factor was considered significantly enriched.
For the TF enrichment analysis on ENCODE ChIP-Seq
data, a Benjamini-Hochberg correction was also performed
to estimate the false discovery rate (FDR) and q-value.
Hierarchical clustering analysis
TF and target genes were subjected to hierarchical cluster-
ing analysis using the Euclidean distance measure and the
Ward. D2 linkage function in Spotfire (TIBCO). Variance,
Skewness, and Kurtosis of dendrogram results were com-
pared to 1000 random permutations of the data.
Comparison of type II and type III EMT programs
We compared DEGs in Type II EMT with a publicly avail-
able dataset from a model of Type III EMT (GSE177708,
NCBI Gene Expression Omnibus). Affymetrix microarrays
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were used to measure gene expression in human adenocar-
cinoma cell line A549 after TGFβ induction of EMT. Genes
in the two datasets were matched by Entrez ID, and
only genes that were common to both datasets, and
detected to be expressed in the microarray, were kept
for further analysis.
Results
Induction of the EMT program
We have previously validated a model of Type II EMT
using a continuously replicating line of human small air-
way epithelial cells (hSAECs) immortalized with human
telomerase (hTERT) and CDK4 expression [21]. These
cells show a stable epithelial morphology and differenti-
ated cytokeratin isoforms after over 100 population dou-
blings, express the stem cell marker p63 and high levels
of p16INK4a, and have an intact p53 checkpoint path-
way [21]. In the absence of TGFβ stimulation, hSAECs
assumed a normal cuboidal morphology with peri-
nuclear cytoplasmic distribution of F-actin, detected by
fluorescence microscopy using confocal microscopy after
staining with Alexa568-conjugated phalloidin (Fig. 1a).
In response to chronic TGFβ stimulation, the cells
acquired an elongated shape with markedly induced
F-actin staining. This morphological change of enhanced
front-rear polarity and actin rearrangement into cytosolic
stress fibers are characteristic morphological changes of
EMT [5, 33].
To demonstrate the induction of the Type II EMT
gene program, the steady state expression of mesenchymal
genes and EMT-associated transcription factors were
assessed by Q-RT-PCR. TGFβ-treatment induced the
expression of FN1, Col1A and VIM by 3,475-, 31- and
20-fold, respectively (Fig. 1b). Similarly, the EMT core
transcription factors SNAIL1, ZEB1 and Twist1 were
induced by 26-, 39- and 4-fold, respectively (Fig. 1b).
Together these data suggest that TGFβ induces mor-
phological and gene signatures of stable Type II EMT
in hSAECs.
Analysis of the EMT gene program
To understand the core EMT program and how TNF
signaling modulates its expression, hSAECs were sub-
jected to TGFβ induced reprogramming, and stimulated
in the absence or presence of TNF for 1 or 12 h. Each
experimental condition was reproduced in triplicate,
representing 18 samples subjected to RNA-Seq analysis
(Fig. 2a). The schema used in RNA sequence analysis is
described in Fig. 2b.
Multidimensional scaling (MDS) was used as an un-
supervised approach to visualize the level of similarity of
the 18 RNA samples (Fig. 2c). MDS is a method similar
Fig. 1 Induction of Type II EMT. a Primary human small airway epithelial cells (hSAECs) were incubated in the absence or presence of TGFβ
(10 ng/mL) for 15 days. Cells were fixed, stained with Alexa568-conjugated phalloidin (for distribution of F-actin, shown in red color) and
DAPI (a nuclear DNA stain, shown in blue color), and examined by confocal microscopy. b Total RNA was extracted, purified, and reverse-transcribed.
The expression of core transcription factors (SNAIL1, Twist1, and ZEB1, upper panel) and mesenchymal markers (Vimentin (VIM), collagen 1A (Col1A), and
fibronectin (FN1), lower panel) were examined by Q-RT-PCR. Shown is fold-change mRNA abundance normalized to cyclophilin. Data are from three
independent experiments
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to principal component analysis that enables high level
representation of RNA Seq data based on similarities in
expression of 500 genes with the largest fold change
difference in the data set. In this analysis, distances were
calculated as leading log-fold-changes between each
sample pair. From Fig. 2c it is readily apparent that
MDS differentiates the RNA seq expression patterns of
the mesenchymal state from that of the epithelial cells in
the first dimension and that of TNFα in the second di-
mension. Although TNF induces very strong effect on
the epithelial cells in the second dimension, the relative
response of the mesenchymal cells is highly compressed
Fig. 2 Experimental perturbation and RNA-Seq analysis. a Experimental design. Triplicate biological replicates were subjected to no treatment
(hSAEC) or TGFβ treatment (hSAEC-EMT). Cells were stimulated with TNFα for 0, 1 or 12 h prior to RNA extraction. b Flow diagram for RNA-Seq
GLM data analysis. Abbreviations: NGS, next generation sequencing; QA/QC, quality assurance/quality control; GLM, generalized linear model; DGE,
differential gene expression. c Multidimensional unsupervised clustering analysis of RNA-Seq data sets. Shown is the similarity of each replicate
based on TGF treatment or time post TNF and their clustering by group. Abbreviations: CE, control (unstimulated) epithelial cells; CM, control
mesenchymal cells
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in the second dimension. Finally, the differences in fold
change between replicates in the same group are very
small relative to the inter-group responses. These analyses
indicated that we had a robust and reproducible dataset
and that chronic TGFβ treatment partially appeared to
mimic acute stimulation of epithelial cells with TNF.
Generalized linear modeling was used to identify genes
that were differentially expressed in the data set; con-
trasts were used to compare the differences between
treatment groups. The results of generalized linear mod-
eling (GLM) are provided in Additional files 2–10. We
first focused on the comparison of the mesenchymal vs
epithelial states. This comparison identified 3,487 differ-
entially expressed genes (DEGs) that met a fold change
cut-off of >2 with a highly significant, Bonferroni cor-
rected pvalue (p < 0.00001). This group of DEGs was
subjected to Ingenuity Pathway Analysis (IPA), where
canonical pathways were ranked by the enrichment of
genes in each process. Here we noted the rank ordered
appearance of “cell death and survival”, “organismal in-
jury and abnormalities”, and “cellular development” were
influenced by the TGFβ-induced EMT (c.f. Fig. 3a, 3b).
Analysis of canonical pathways further showed that NF-
κB/RelA-signaling pathway was significantly enriched in a
network with SP1 and STATs (Fig. 3c), factors known to
modulate RelA-dependent signaling [34, 35].
Transcription factor enrichment of the EMT
An unbiased transcription factor (TF) enrichment analysis
was performed on the DEGs. In this analysis, 345 distinct
TF experiments of ChIP-chip, ChIP-Seq, ChIP-PET or
DamID were tested for TF enrichment using hypergeo-
metric probability distribution [31]. Here, we only consider
the enriched TFs from 148 DNA binding experiments per-
formed on human cells. Of these, 47 distinct TF experiment
datasets were significantly enriched for the 3,487 DEGs in
EMT. The enriched TFs are shown in Table 4, ranked by
enrichment fold ratio and associated with the number of
upregulated genes. Many of these TFs are linked to EMT in
the literature. Of these, SMADs were among the top highly
enriched TFs, consistent with their known role in mediat-
ing canonical TGFβ signaling [16]. Also included in the top
list was tripartite motif containing 28 (TRIM28), an epigen-
etic modulator regulating histone H3 modifications on E-
cadherin and N-cadherin promoters [36]. SOX2 promotes
tumor metastasis by stimulating EMT via regulation of the
WNT/β-catenin signal network [37]. ESR1 and ESR2, re-
ported to suppress EMT [38, 39], were also significantly
enriched. The CLOCK TF binds the E-box of PER2 and
regulates this and other circadian rhythm genes, which are
reported to be involved in EMT [40].
The tumor suppressor TP53 is known to regulate
EMT [41, 42]. We observed that p53-related TP63,
IRF1, TFAP2C, CTNNB1, AHR1, ELF5, FOXM1 and
FOXO3 were also exclusively enriched TFs for downreg-
ulated DEGs (Table 5). Among these, TP63 attenuates
EMT in prostate cells [43] and alternatively spliced iso-
form ΔNp63α inhibits EMT in human bladder cancer
cells [44]. IRF1 is a tumor suppressor modulated by
miR-23, promoting TGF-beta-induced EMT in lung can-
cer [45]. TFAP2C governs the luminal epithelial pheno-
type in mammary development and carcinogenesis [46].
AHR1 was reported to inhibit TGFβ-induced EMT [47];
ELF5 inhibits Type I EMT in mammary gland develop-
ment and Type III EMT in breast cancer by transcrip-
tionally repressing SNAIL2 [48]. Constitutive activation
of CTNNB1 stabilized mesenchymal phenotypes of epi-
thelial cells [49]. Of relevance to the hypothesis devel-
oped in this work, we noted that NF-κB/RelA was
among the top significantly enriched TFs, with ChIP-Seq
binding sites for 152 of the 1477 upregulated genes in the
EMT data set, indicating that NF-κB/RelA dependent
genes may play an important role in Type II EMT.
The depleted TFs based on the ChEA ChIP-X data set
include ELF1, GABP, KDM6A, EST1, ETS1 (Tables 6, 7),
suggesting that these TFs may be involved in the reversal
of EMT, termed MET. GABP has a predicted binding
site on miR200c, an important effector of EMT in im-
mortalized mammary epithelial cells, MCF12A [41].
KDM6A was reported to regulate the expression of TFs
critical for stem cell differentiation. EMT is a process of
dedifferentiation and gain of stemness, which may ex-
plain the depletion of this TF in Type II EMT. EST1 and
ETS1 have not yet been reported to be involved in MET.
Although our TF enrichment results may be affected by
limited experiments in the public databases of human
epithelial cells, this analysis has generated valuable hy-
potheses on the TFs involved in EMT, most of which are
supported by the literature.
Further comparison of the TF enrichment analysis in-
dicated that the 30 enriched TFs for upregulated DEGs
significantly overlapped with the 40 TFs associated with
downregulated DEGs (p-value = 4.3e-13), with 18 TFs in
common (Tables 4 and 5). A similar finding was ob-
served with depleted TFs in the EMT DEGs (Tables 6
and 7), suggesting that many transcription factors are bi-
modal, i.e., they both inhibit or activate the target genes
depending on the chromatin environment.
Topographical map of EMT regulated transcription factors
and target genes
We next sought to map the relationships between TFs
and target genes controlling EMT. In this analysis, hier-
archical clustering identified three significant TF clusters
and two DEG clusters (Fig. 4). The gene clusters corres-
pond to genes that were either up- or downregulated by
EMT. Conversely, we noted that each TF is associated
with both up- and down-regulated target genes, indicating
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bimodal behavior consistent with the above TF enrich-
ment analysis. The TF cluster A contains TP63 and
Smad2/3. Both Smad 2 and 3 regulate relatively fewer
DEGs, some of which are coregulated by EGR and SOX2.
TF cluster B contains RelA, BTB and CNC homology 1
(BACH1), globin transcription factor (GATA1/2), and
MYC proteins; TF cluster B regulates a distinct group of
DEGs from those regulated by cluster A, but also a
Fig. 3 Functional analysis of differentially expressed genes in EMT. a Ingenuity pathway analysis (IPA) is shown for genes expressed in control
hSAECs. X axis, category rank; Y axis, number of subcategories in each pathway. b IPA for genes in hSAEC-EMT. Note the cell death and survival
and organismal injury and abnormality become the 2nd and 4th ranked pathway. c Enriched TNF signaling pathway identified by IPA in DEG data
set. Intensity of red hue is proportional to upregulation by EMT
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bimodal fashion. Cluster C is the largest group of TFs
containing estrogen receptor (ESR1/2), forkhead box 03
(FOXO3), TRIM28 and others, and is associated with the
fewest up- or downregulated DEGs.
Type II EMT program controls biological functions distinct
from than that of Type III EMT
Because Type II EMT occurs in primary epithelial cells
without background oncogenic K-ras mutations charac-
teristic of epithelial tumors [50], we hypothesized that
Type II EMT induces distinct gene expression profiles.
Differences in gene regulation between Type II EMT
and Type III EMT may help identify pathways that are
specifically involved in fibrosis (Type II EMT) vs inva-
sion and metastases (Type III EMT). We therefore com-
pared the TGFβ-induced gene expression patterns in
primary hSAEC with that of an established human
epithelial alveolar carcinoma cell, A549. A549 cells
are K-Ras activated, keratin positive epithelial cells
with features of the lower airways [51, 52]. For this
purpose, we compared our Type II model dataset with a
publicly available Type III model dataset (GSE177708,
NCBI Gene Expression Omnibus). Affymetrix microarrays
were used to measure gene expression in Human adeno-
carcinoma cell line A549 after TGFβ induction of EMT.
Genes in the two datasets were matched by Entrez ID,
Table 4 Significantly enriched human transcription factors for upregulated genes in the EMT process. The enriched transcription
factors (TFs) were inferred by comparing ChIP-Seq or ChIP-chip identified target genes (TGs) of each TF with the upregulated DEGs
in the EMT process. The enriched TFs were sorted according to the enriched fold ratios
Human TFs PMID # total TGs # DETGs Fold ratio Corrected p-value Cell lines
TRIM28 21343339 85 21 3.9 1.8E-05 HEK293
ESR1 21235772 213 36 2.7 4.8E-04 MCF-7
CLOCK 20551151 398 58 2.3 2.3E-05 293 T
ESR2 21235772 392 57 2.3 9.1E-07 MCF-7
SMAD3 21741376 1074 144 2.1 1.4E-06 HESC
SOX2 20726797 2060 275 2.1 <3.45E-14 SW620
RELA 24523406 1147 152 2.1 <3.45E-14 A549
BACH1 22875853 1183 150 2 <3.45E-14 HELA-AND-SCP4
GATA1 19941826 700 84 1.9 3.8E-14 K562
TP53 18474530 734 88 1.9 4.4E-06 U2OS
GATA2 21666600 634 75 1.9 2.1E-06 HMVEC
PAX3-FKHR 20663909 975 115 1.9 4.8E-05 RHABDOMYOSARCOMA
SMAD4 21741376 2032 237 1.8 2.4E-08 HESC
DROSHA 22980978 441 51 1.8 <3.45E-14 HELA
ZNF217 24962896 1400 160 1.8 8.7E-03 MCF7
NFE2L2 22581777 508 58 1.8 4.7E-11 LYMPHOBLASTOID
EOMES 21245162 861 98 1.8 3.7E-03 HESC
SMAD2 18955504 1643 184 1.8 4.1E-06 HaCaT
SMAD3 18955504 1643 184 1.8 3.8E-12 HaCaT
NR3C1 21868756 1023 111 1.7 3.8E-12 MCF10A
DNAJC2 21179169 803 87 1.7 6.1E-06 NT2
EGR1 20690147 5216 549 1.7 2.4E-04 ERYTHROLEUKEMIA
SOX2 21211035 2830 288 1.6 <3.45E-14 LN229_GBM
GATA2 19941826 1727 175 1.6 <3.45E-14 K562
MYC 19915707 1793 177 1.6 8.5E-08 AK7
AR 19668381 2958 291 1.6 5.0E-07 PC3
ATF3 23680149 1995 193 1.5 8.8E-13 GBM1-GSC
SMAD4 21799915 2302 220 1.5 4.3E-07 A2780
GATA1 21571218 2388 228 1.5 7.2E-08 MEGAKARYOCYTES
PMID pubmed article number; # total TGs number of ChIP-Seq or ChIP-chip identified target genes (TGs) of each TF; #DETGs number of differentially
expressed genes
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Table 5 Significantly enriched human TFs for the downregulated genes in the EMT process. The enriched transcription factors (TFs)
were inferred by comparing ChIP-Seq or ChIP-chip identified target genes (TGs) of each TF with the downregulated DEGs in the
EMT process. The enriched TFs were sorted according to the enriched fold ratios
Human TFs PMID # total TGs # DETGs Fold ratio Corrected p-value Cell lines
TP63 17297297 34 14 3.9 1.1E-04 HaCaT
TRIM28 21343339 85 22 3 7.4E-04 HEK293
ESR2 21235772 392 98 2.9 <3.45E-14 MCF-7
CTNNB1 24651522 138 30 2.5 6.5E-04 LGR5+ INTESTINAL STEM CELL
SOX2 20726797 2060 433 2.4 <<3.45E-141.0E-16 SW620
IRF1 21803131 326 67 2.4 5.9E-09 MONOCYTES
TFAP2C 20629094 1125 229 2.4 <3.45E-14 < 3.45E-14 < 3.45E-14 MCF7
ESR1 21235772 213 43 2.3 4.1E-05 MCF-7
ZNF217 24962896 1400 271 2.2 <3.45E-14 MCF7
FOXM1 23109430 253 47 2.2 1.4E-04 U2OS
NR1H3 23393188 574 104 2.1 8.6E-11 ATHEROSCLEROTIC-FOAM
CDX2 20551321 383 69 2.1 1.2E-06 CACO-2
BACH1 22875853 1183 211 2.1 <3.45E-14 HELA-AND-SCP4
AHR 22903824 621 109 2 1.9E-10 MCF7
FOXO3 23340844 650 114 2 5.9E-11 DLD1
AR 21909140 258 45 2 1.5E-03 LNCAP PROSTATE CANCER CELL LINES
TP53 16413492 276 48 2 7.8E-04 HCT116
SMAD2 18955504 1643 285 2 <3.45E-14 HaCaT
SMAD3 18955504 1643 285 2 <3.45E-14 HaCaT
TP53 18474530 734 122 1.9 3.9E-10 U2OS
RELA 24523406 1147 187 1.9 <3.45E-14 A549
TP63 23658742 3355 541 1.9 <3.45E-14 EP156T
ARNT 22903824 912 147 1.9 2.2E-11 MCF7
SMAD4 19686287 348 56 1.9 1.4E-03 HaCaT
TCF4 18268006 392 63 1.9 3.9E-04 LS174T
CLOCK 20551151 398 62 1.8 1.3E-03 293 T
PAX3-FKHR 20663909 975 144 1.7 3.1E-08 RHABDOMYOSARCOMA
TP63 22573176 3867 570 1.7 <3.45E-14 HFKS
GATA1 19941826 700 103 1.7 1.9E-05 K562
SMAD3 21741376 1074 158 1.7 4.8E-09 HESC
CTNNB1 20460455 900 130 1.7 1.1E-06 HCT116
FOXA2 19822575 2791 402 1.7 <3.45E-14 HepG2
SMAD4 21741376 2032 290 1.7 <3.45E-14 HESC
ELF5 23300383 920 130 1.6 4.2E-06 T47D
GATA2 19941826 1727 241 1.6 5.2E-12 K562
TRIM28 17542650 680 94 1.6 1.2E-03 NTERA2
GATA2 21666600 634 87 1.6 3.6E-03 HMVEC
AR 19668381 2958 398 1.6 <3.45E-14 PC3
HNF4A 19761587 816 108 1.5 1.7E-03 HUMAN INTESTINAL CELL LINE CACO-2
AR 22383394 1690 221 1.5 4.3E-08 PROSTATE_CANCER
PMID pubmed article number; # total TGs number of ChIP-Seq or ChIP-chip identified target genes (TGs) of each TF; #DETGs number of differentially
expressed genes
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and only genes that were common to both sets, and de-
tected to be expressed in the microarray, were kept for
analysis.
We identified 137 genes upregulated in Type II- but
not in Type III-EMT, and 124 genes upregulated in Type
III- but not in Type II EMT. Fig. 5 (top) illustrates the
top 10 canonical pathways for genes uniquely induced in
Type II EMT. In this plot, both the p value and ratio of
enrichment are presented for each pathway. Here, lipid
metabolism and thrombin signaling pathways were the
most statistically significant. By contrast, Fig. 5 (bottom)
displays the top 10 canonical pathways for genes uniquely
induced in Type III EMT. Plasma membrane estrogen
receptor signaling, ErbB receptor signaling and glycipan
pathways were the most highly significant, consistent with
the effect of Type III EMT on cellular motility, invasion
and metastasis. Together these data suggest that the in-
duction of Type II EMT produces a cellular biology state
distinct from that seen in Type III EMT.
Modulation of the TNF response by Type II EMT
NF-κB is an inducible transcription factor that is regu-
lated by a rapid release from cytoplasmic IκBα stores,
followed by a slower release from 105 kDa NFκB2
complexes referred to as the canonical and noncanonical
pathways respectively [53, 54], producing sequential
waves of NF-κB dependent gene expression [55, 56].
Our mechanistic studies have found that the noncanoni-
cal pathway is coupled to the canonical pathway activa-
tion at a fixed time interval. This coupling is due to a
feed-forward pathway mediated by inducible expression of
the rate-limiting signaling adapter, TRAF1, that triggers ac-
tivation of the noncanonical pathway [57]. Recently we ob-
served that that the EMT state produces profound changes
in canonical-noncanonical pathway coupling through tran-
scriptional reprogramming of TRAF1 and NFκB2 pro-
moters [5, 58]. As a result, the “coupling constant” e.g., the
lag time between activation of the canonical and the nonca-
nonical NF-κB program, was markedly reduced by EMT.
We therefore hypothesized that TGFβ-induced EMT
produced profound differences in the response to activating
the TNF signaling pathway. We first compared the TGFβ-
regulated gene network with that induced by TNF stimu-
lation. Of the 3,487 DEGs detected in EMT, 547 were also
regulated by TNF, indicating that the two signaling pathways
are highly overlapping (Fig. 6a). The expression patterns of
the TNF-dependent EMT regulators were examined. To re-
duce noise, the data set was filtered to only the more robustly
Table 6 Significantly depleted human TFs for the upregulated genes in the EMT process
Human TFs PMID # total TGs # DETGs Fold ratio Corrected p-value Cell lines
ELF1 17652178 99 0 Inf <3.45E-14 JURKAT
GABP 17652178 655 9 4.6 2.2E-08 JURKAT
EST1 17652178 636 9 4.5 6.4E-08 JURKAT
ETS1 20019798 1446 28 3.3 2.8E-14 JURKAT
KDM6A 18722178 410 9 2.9 7.4E-03 U937_AND_SAOS2
FOXP3 21729870 1300 43 1.9 6.1E-05 TREG
VDR 23849224 2029 69 1.9 9.1E-08 CD4+
GABP 19822575 2430 92 1.7 7.2E-07 HepG2
HOXC9 25013753 1858 72 1.6 1.7E-04 NEUROBLASTOMA BE2-C
The depleted transcription factors (TFs) were inferred by comparing ChIP-Seq or ChIP-chip identified target genes (TGs) of each TF with the upregulated DEGs in
the EMT process. Depleted TFs were sorted according to the depleted fold ratios
PMID pubmed article number; # total TGs number of ChIP-Seq or ChIP-chip identified target genes (TGs) of each TF; #DETGs number of differentially
expressed genes
Table 7 Significantly depleted human TFs for the downregulated genes in the EMT process. The depleted transcription factors (TFs)
were inferred by comparing ChIP-Seq or ChIP-chip identified target genes (TGs) of each TF with the downregulated genes in the
EMT process. The depleted TFs were sorted according to the depleted fold ratios
Human TFs PMID # total TGs # DETGs Fold ratio corrected P-value Cell Lines
GABP 17652178 655 16 3.5 2.8E-09 JURKAT
KDM6A 18722178 410 14 2.5 2.2E-03 U937_AND_SAOS2
ETS1 20019798 1446 59 2.1 3.3E-10 JURKAT
EST1 17652178 636 28 2 3.3E-03 JURKAT
GABP 19822575 2430 132 1.6 4.4E-08 HepG2
PMID pubmed article number; # total TGs number of ChIP-Seq or ChIP-chip identified target genes (TGs) of each TF; #DETGs number of differentially
expressed genes
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expressed 249 genes and subjected to hierarchical clustering,
resulting in 6 major clusters (A-F, Fig. 6b). Cluster A repre-
sented early genes activated in hSAECs and silenced in
EMT; Cluster B represented genes downregulated by TNF in
hSAECs and not expressed in EMT; Cluster C represented
late genes activated in hSAECs and whose expression was
potentiated in EMT; Cluster D represented late genes acti-
vated in hSAECs and silenced in EMT; Cluster E represented
early genes in hSAECs and potentiated by EMT; finally
Cluster F represented genes not activated by TNF in
hSAECs, but strongly upregulated by TNF in EMT in a late
expression pattern. TF enrichment analysis identified 13
shared transcription factors controlling these 6 clusters in-
cluding androgen receptor (AR), GATA1/2, MYC, NANOG,
NR0B1, NR1H3, RelA, SMAD2/3, STAT3, TP-53 and −63
(not shown). These are members from all three of the major
TF clusters associated with the EMT program (Fig. 4).
The hierarchical clustering analysis suggested that the
TNF pathway elicits distinct biological functions in epi-
thelial cells versus that after Type II EMT. We therefore
examined the function of genes activated by TNF in
hSAECs but not activated after EMT, and those activated
Fig. 4 Transcription factor-target gene topological analysis. Hierarchical clustering analysis was conducted on 109 transcription factors (gene
names of the enriched transcription factors from 47 experiments are shown in columns) and DEGs associated with EMT using the Euclidean dis-
tance measure and the Ward. D2 linkage function. Variance, Skewness, and Kurtosis dendrogram results were compared to 1000 random permutations
of the data. Three significant clusters, labeled A, B and C are identified at top. The three clusters were highly significant (p < 0.001)
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after EMT but not in hSAECs. From this analysis, inter-
feron signaling and immune system activation were
prominent in hSAECs (Fig. 6c, top). By contrast, integrin
signaling was upregulated by TNF in the EMT back-
ground (Fig. 6c, bottom). Integrin αV signaling is par-
ticularly important because other studies have
demonstrated that integrin signaling drives the mainten-
ance of the EMT state [59], providing an additional
cross-talk mechanism for how cytokine signaling rein-
forces EMT.
Analysis of TNF-dependent genes common to both
epithelial and mesenchymal states, revealed that
NFKBIE/IκBα is found in Cluster E. NFKBIE/IκBα is a
prototypical early-response gene that we showed earlier
was potentiated by EMT. In contrast, TNFAIP1/Naf1, a
prototypic late gene under noncanonical NF-κB pathway
control is found in Cluster F consistent with our earlier
observations [5, 55–57]. Together we conclude that
TGFβ-induced EMT produces complex modifications of
the TNF response program through both potentiation
and inhibition of distinct gene subnetworks.
RelA is essential for TGFβ-induced Type II EMT
Together, the findings that TGFβ induces a gene expres-
sion profile similar to that of TNF (Fig. 2), a significant
fraction of TGFβ-regulated genes are NF-κB target genes
(Table 4), and that TGFβ induces a core of TNF-induced
NF-κB-regulated genes (Fig. 6a) led us to investigate the
relationship of NF-κB activation with EMT.
Earlier studies have shown that TGFβ is coupled to
NF-κB activation in carcinoma cells by oncogenic trans-
formation induced expression of the TGFβ-associated
kinase, TAK1 [60]. Whether TGFβ is coupled to NF-κB
activation in primary cells without TAK1 amplification is
not known. We therefore measured the relative abun-
dance of nuclear RelA in response to TGFβ-stimulation.
We observed a 2.5-fold induction of nuclear RelA 1 h
after TGFβ stimulation (Fig. 7a, top panel). We noted
Fig. 5 Unique pathways for Type II and Type III EMT. Shown are unique pathways associated with TGFβ-induced Type II EMT (top) and Type III
EMT (bottom). Primary y-axis is the Ratio of Enrichment (R) while secondary y-axis is adjusted P-value as calculated by the hypergeometric test.
The test is applied to evaluate the significance of enrichment (R), given as p-value (adjP). The value R is calculated by R = k/ke, where k = number
of genes in our set present in a given pathway, and ke = expected value of k based on the reference set present in the same pathway
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that this induction was weaker than the 5-fold induc-
tion induced by the prototypical TNFα ligand; to-
gether there was no additive effect of the two ligands
(Fig. 7a, lower panel).
Two strategies were used to determine the functional
requirement of RelA in TGFβ-induced EMT. First, the
induction of EMT was examined in RelA−/− mouse em-
bryonic fibroblasts (MEFs). Here, the expression of
TGFβ-induced SNAIL1, IL-6 and ZEB1 were completely
blocked in RelA−/− MEFs compared to RelA WT MEFs
(Fig. 7b). Second, we measured the effect of IKK inhib-
ition on a time course experiment of TGFβ stimulation
in epithelial cells. For this purpose, we used a highly se-
lective, allosteric inhibitor of IKK (BMS-345541); this
compound does not affect the JNK, MAPK or Jak-STAT
pathways [22]. We observed that TGFβ stimulation
produced a complex pattern of SNAIL1 expression, with
a rapid peak of 30-fold induction after 2 days, followed
by a decline, with a second peak of 40-fold induction
after 5 days of treatment (Fig. 7c). By contrast, in epithe-
lial cells treated with BMS-345541 at concentrations of
1, 3 and 10 μM respectively, SNAIL1 mRNA expression
was significantly reduced at all time points measured.
The patterns of ZEB1 and Twist1 showed a monotonic
increase in expression peaking ~6 days after treatment
at 40-fold and 3-fold inductions relative to untreated
hSAECs, respectively. Similar to the effect on SNAIL1,
BMS-345541 significantly reduced ZEB1 expression and
completely blocked Twist1 expression (Fig. 7c). Similar
patterns of inducible expression and BMS inhibition
were observed for the mesenchymal cytoskeletal genes,
VIM, FN1 and IL-6 (Fig. 7c). Together these data
Fig. 6 TGF treatment induces a core of TNF regulated genes. a Venn diagram of the overlap of TGF regulated genes (CMvsCE) with those
induced by TNF at 1 h (T1EvsCE) and 12 h (T12EvsCE) in hSAECs. The overlapping genes between TGF state (CMvsCE) and both or either of TNF
1 h or 12 h were considered for further analysis. This gene set amounts to 547 genes. b. Heat map of TNF regulated EMT genes. a clustered
image heatmap of a normalized matrix was created that correlates gene expression pattern of 249 genes to the time course in HSAECs upon
stimulation by TNFα and TGFβ. For each gene, mean and standard deviation were calculated from their expression values across the time course
and were normalized to unstimulated HSAECs. Z-score transformation was applied for each gene [5]. Hierarchical clustering was performed using
an average-linkage clustering algorithm across the time points in the absence or presence of stimulants. The cluster tree of genes is represented
on the y-axis, and time-points and stimulants are shown on the x-axis. Each block of red or green represents a high positive or negative correlation
between the gene expression and the stimulant under a specific time point. The list of genes in each cluster are shown in Table 8. (C) Top 10 pathways
uniquely associated with TNF-induced genes in epithelial cells (top) and mesenchymal cells (bottom). Primary y-axis is the Ratio of Enrichment (R);
secondary axis is adjusted P value (described in Fig. 5)
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Table 8 Gene list in each of the six clusters obtained from hierarchical clustering analysis of 249 genes upon stimulation by TNFα in
epithelial and mesenchymal state. Each cluster corresponds to that in Fig. 6b
Cluster A Cluster B Cluster C Cluster D Cluster E Cluster F
1 RNF19B DUSP6 SNCAIP PIM3 PLAUR SLC2A6
2 IRF1 EGR1 TNFAIP2 CLDN1 MAFF SYNPO
3 GBP1 DUSP5 CSF1 SERPINB1 NKX3-1 TLR2
4 TNFSF15 SLITRK6 DRAM1 STARD5 IL6 COL12A1
5 BTG2 MAT2A IKBKE KRT6B IL8 FEZ1
6 SPRR2D NAB2 SLC39A8 GBP2 PTX3 PID1
7 HCAR3 CYP1A1 DHRS3 TNF MGLL
8 HCAR2 FAM110C SPRR1A CXCL3 SERPINE2
9 IL1RN KIAA1551 ITGB8 CXCL2 LBH
10 TNFAIP8 FBXW7 ANKRD33B NFKBIZ TNC
11 FOSB SGK223 PI3 CSF2 MMP9
12 NR4A1 EMP1 CDC42EP4 IL1A IL7R
13 NCOA7 SPRY2 LYPD3 IL1B LAMB3
14 SERPINB2 TIPARP LPAR6 NFKBIA PIK3IP1
15 ARL5B SRF PRSS8 NFKBIE NAMPT
16 ITPKC TGIF1 DDX58 NUAK2 ITGA5
17 GATA6 FOSL1 C1orf226 LIF DNER
18 SDC4 GADD45A ISG15 TNFAIP3 GPR176
19 RAP2B CXCL16 TNFAIP6 TGM2
20 OVOL1 SLPI JPH2
21 PIM1 OAS1 COL27A1
22 HBEGF TGM1 STC2
23 EREG MUC1 FSTL3
24 TRIB1 PSTPIP2 SOX4
25 EGR3 SCNN1G DUSP1
26 PHLDA2 SRD5A1 ST3GAL1
27 MAP3K14 S100A8 FADS3
28 LRIG1 MMP28 BHLHE40
29 KRT15 PRODH RHOB
30 HAS3 IFIH1 SPRY4
31 IFFO2 ASS1 AKAP12
32 AKR1B10 GCLC ANGPTL4
33 CKB LRRC8D DLC1
34 CALML3 OAS3 THBS1
35 SLC2A1 UBE2L6 SEMA7A
36 AQP3 IFI6 NNMT
37 IL6R TAP1 ICAM1
38 SESN3 PSMB10 XBP1
39 ZNF462 HLA-F CXCR7
40 DST CDKN1C MSC
41 HR ALDH2 CXCL1
42 C1orf116 SQRDL CSF3
43 WEE1 STAP2 ZC3H12A
Tian et al. BMC Genomics  (2015) 16:529 Page 16 of 23
indicate that IKK-NF-κB/RelA activation is a necessary
component of the TGFβ-induced EMT program.
Discussion
Type II EMT is a dynamic process that mediates airway
response to injury, stimulating basal epithelial cells to
promote re-epithelialization and extracellular matrix
remodeling. EMT transcriptional reprogramming is a
coordinated intracellular response triggered by epithelial
growth factors (TGF, EGF) signaling via tyrosine kinase-
coupled receptor growth factors to converge on a core
set of transcription factors including SNAIL1, ZEB1,
Twist1, and others. EMT is further modulated by
intercellular signaling cross-talk through innate inflam-
matory cytokines, extracellular matrix and ROS stress.
In this study, we employed a well-established model of
TGFβ-induced Type II EMT in primary telomerase-
immortalized hSAECs to understand the gene expression
programs responsible for EMT in normal cells and how
they are modified by the innate response. Surprisingly we
observe that TGFβ influences a 3,487 member gene net-
work, 547 of which are also controlled by TNF. By com-
parison to genome-wide ChIP-Seq data sets, we observe
that this core pathway is enriched in genes under NF-κB/
RelA control. We infer distinct biological functions com-
pared to Type III EMT, demonstrate re-routing of the TNF
Table 8 Gene list in each of the six clusters obtained from hierarchical clustering analysis of 249 genes upon stimulation by TNFα in
epithelial and mesenchymal state. Each cluster corresponds to that in Fig. 6b (Continued)
44 GJB2 PRKAG2 INHBA
45 TSC22D1 SGPP2 SERPINA1
46 CYP1B1 C1R EDN1
47 BCL10 TRANK1 G0S2
48 ALDH1A3 APOL6 LOC284454
49 PHLDA1 PARP14 BMP2
50 ERRFI1 CXCL10 DKK3
51 TCF4 BIRC3 DKK1
52 STK40 TYMP SMAD7
53 AP5B1 CD74 PTPRE
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Fig. 7 (See legend on next page.)
Tian et al. BMC Genomics  (2015) 16:529 Page 18 of 23
pathway and experimentally demonstrate the functional
role of NF-κB activation in Type II EMT. Finally, we note
that the response of the TNF network is markedly affected
by the EMT state, with distinct arms of the response being
silenced, while others are enhanced. These studies are the
first to our knowledge that demonstrate the unique TGFβ
signatures in inducing Type II EMT and the requirement
of NF-κB in this process.
TGFβ-induced Type II EMT
TGFβ activates cells by TGFβ receptor type II (TGFβRII),
a transmembrane serine- threonine kinase that recruits
and phosphorylates TGFβRI on the cell membrane [7].
Activated TGFβRI triggers two inter-related pathways,
known as the canonical (SMAD-dependent) and nonca-
nonical (ERK/MAPK-dependent) pathways, that converge
on a core set of transcription factors responsible for coor-
dinated suppression of epithelial genes and induction of
mesenchymal genes. In the canonical pathway, the acti-
vated TGFβRI/II complex phosphorylates cytoplasmic
Smads 2/3 that bind to Smad4. This trimeric Smad com-
plex binds to regulatory sequences in the E cadherin
promoter, leading its repression and subsequent loss
of adherens junctions [12]. In our study, we have
found that SNAIL1 expression is the most rapidly in-
duced member of the core EMT regulators (Figs. 1b
and 7c). Based on its rapid appearance, we suggest
that SNAIL1 expression is one of the early triggers of
Type II EMT. The absence of SNAIL1 in the public
ChIP-Seq datasets prevented its enrichment and target
gene analysis.
Other work has shown that the activated Smad 2/3/4
trimer also binds to Smad-binding elements in the regu-
latory regions of JunB and c-Jun genes, inducing their
interaction with other coactivators including the EP300
coactivator [9]. This result indicates that the activities of
the EMT core TFs are modulated by the EMT state, pro-
ducing a bi-modal behavior, both activating and inhibit-
ing gene expression. To this end, we note that over half
of the TFs identified by enrichment analysis associated
with upregulated DEGs in EMT are also associated with
the downregulated genes in EMT. We note that these
TFs include Smad2/3, RelA, SOX2 and others. Of rele-
vance here, our earlier inference of RelA modulator-
target gene triplets showed 6 patterns of modulator
interaction with RelA involved in activation and inhib-
ition of specific target genes within biologically relevant
pathways [35]. In extension of these studies, we pre-
dicted that FN1 and FOXP1 function as modulators of
RelA action in the setting of EMT [61]. These latter pre-
dictions suggest that the target genes and behavior of
RelA are influenced by the EMT. It will be of interest to
develop systems-wide maps of the effects of TGFβ on
expression of modulators for the NFκB/RelA and other
EMT-regulated TFs.
Activated TGFβRI complex triggers a Smad-independent
(“noncanonical”) pathway through the PI3K/Akt, Ras small
GTPases, Wnt/β-catenin, ERK, p38, and JNK kinases [7].
Although the actions of Smads are dominant on EMT, sig-
naling through the noncanonical pathway is required for
the full expression of EMT. Recent findings in non-small
cell lung cancer cell lines indicate that phospho-Erk1/2
mediates a decrease in ECad and an increase in FN1
expression [62]. Also, inhibition of JNK, p38 and Akt activ-
ities without affecting Smad phosphorylation blocks
TGFβ1 induced α-SMA, SNAIL1 and col1A in primary
alveolar epithelial cells [63]. Together, these data indicate
that Smad signaling is necessary but not sufficient for
EMT. In the TF-TG topology map of EMT (Fig. 4), we
note that the core TFs are clustered into three major clus-
ters. We suggest that the TGs associated with Cluster A,
containing Smad 2/3/4, TP63 and SOX2, are genes down-
stream of the canonical TGFβ signaling pathway.
Transcription factors controlling Type II EMT
We computed the over-representation of 148 TF targets
from publically available ChIP-chip, ChIP-Seq, ChIP-
PET or DamID data [38] using a hypergeometric prob-
ability distribution to tentatively identify regulators of
the DEGs in EMT. 18 of the 30 enriched transcription
factors in the EMT upregulated genes overlapped with
the 40 transcription factors regulating the EMT down-
regulated genes (p-value = 4.3e-13), indicating that these
18 had bimodal activities in a target gene dependent
manner. Many of have been associated with EMT. In
addition to Smad and TP63 proteins discussed above,
NF-E2-related factor-2 (NFEL2l2/Nrf2) is negatively reg-
ulated by E-cadherin expression, whose downregulation
(See figure on previous page.)
Fig. 7 Requirement of NFκB signaling for TGFβ induced Type II EMT. a Cytoplasmic and nuclear extracts from hSAECs with or without EMT were
isolated. 100 μg of cytoplasmic or nuclear extracts were processed for Western blot using anti-RelA Ab (upper panel). Lamin B and tubulin were
detected as loading control Abs respectively. Low left panel: epithelial cells or mesenchymal cells were stimulated with 25 μg/ml TNF for 1 h and
processed for RelA Western blot. Lower right panel: Quantification of nuclear RelA from Odyssey infrared imager. * P < 0.05 compared with control
epithelial cells. b Wild-type (WT) or RelA−/− mouse embryonic fibroblasts (MEF) were incubated with TGFβ for 0, 1, 2, 3 days respectively. Total
RNA was extracted and expression of EMT core transcription factors (SNAIL1 and ZEB1) and NF-κB-dependent genes (IL-6) were measured by
Q-RT-PCR. The data shown is from n = 3 independent experiments. c Epithelial cells were stimulated with TGFβ for various times in the absence
or presence of a small molecule IκB kinase inhibitor (BMS-345541, 1, 3, and 10 μM respectively). The expression of SNAIL1, Twist1, VIM, ZEB1, FN1
and IL-6 were measured by Q-RT-PCR. The data shown are from n = 3 experiments
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may promote Nrf2 nuclear translocation, resulting in the
enhanced resistance of transformed cells to ROS stress
[64]. The transcriptional repressor BACH1 has been
shown to be upregulated in metastable Type III EMT
[65]. We note that RelA and BACH1, GATA1, GATA2
and TFAP2C are enriched in the upregulated genes,
whereas only TFAP2C is enriched in the downregulated
gene set. This observation suggests to us that the activa-
tion mode of RelA is modulated by association of dis-
tinct coactivators, discussed below. Further dissection of
this transcription network will be of interest. For ex-
ample, the implication of the histone acetyltransferase,
CLOCK, in the EMT program and depletion of KDM6A
have not been reported to our knowledge and merits
further investigation.
TNF and TGFβ cross-talk
TGFβ-induced EMT is modulated by a variety of signals
including cytokine stimulation, morphogen signaling,
and ECM interactions. Of relevance here, studies of
transformed alveolar basal epithelial cells show that
TGFβ-induced EMT is accelerated by the presence of
members of the proinflammatory TNF/ IL-1 superfamily
of cytokines [16, 17]. TNF/ IL-1 signal through highly
conserved death domain containing receptors activating
downstream Ras GTPase, p38 MAPK and JNK path-
ways, shared components of the noncanonical TGFβ sig-
naling pathway [7, 58]. By contrast to this modulatory
role our observations in normal epithelial cells indi-
cate that the TNF signature is a major component of
TGFβ-induced EMT (Fig. 5a). Pathway analysis of the
DEGs in EMT indicates enrichment of TNFR signal-
ing pathways (Fig. 3d) and we observe statistically sig-
nificant enrichment of RelA target genes mapping to
ChIP-Seq datasets (Table 4).
Requirement of NF-κB in Type II EMT
NF-κB is a master regulator of airway inflammation and
cell fate determination. Our previous genome-wide ana-
lysis using whole genome-wide RNA-Seq and ChIP-Seq
approaches have shown that this transcription factor
regulates a ~4,000 member gene network mediating
anti-apoptosis, inflammation, and adaptive immunity
[34, 66]. In studies of cancer-associated Type III EMT,
NF-κB is required for IGF-induced EMT by directly in-
ducing SNAIL1 [67]. NF-κB has also been shown to up-
regulate ZEB1/2 and Twist1 [20], explaining, in part,
how the IL-1/TNF superfamily of cytokines mediates
Type III EMT. Our studies indicate that SNAIL1 is the
earliest upregulated core transcription factor in Type II
EMT and whose significant induction precedes that of
ZEB1 and Twist1, leading us to suggest that SNAIL1 is
an initial trigger of EMT.
Our study here shows that chronic TGFβ stimulation
induces nuclear translocation of NF-κB/RelA. Other
studies have shown that TGFβ is a potent activator of
NF-κB/RelA in Ras-transformed cell lines. However, the
relevance of these findings to normal epithelial cells is
confounded by the observations that K-ras is a potent
activator of NF-κB [68], and that oncogenic transform-
ation induces expression of the TGFβ-associated kinase,
TAK1, coupling NF-κB to TGFβRI [60]. Our western
blot quantification indicates that TGFβ treatment in pri-
mary epithelial cells weakly induces NF-κB/RelA trans-
location at levels significantly less than the prototypical
TNF monokine (Fig. 7a).
NF-κB/RelA translocation is controlled by two distinct
pathways controlling sequential waves of NF-κB
dependent gene expression [55, 56]. The canonical path-
way liberates cytoplasmic NF-κB/RelA from IκBα com-
plexes in response to IKKα∙IKKβ [54], whereas the
noncanonical cross-talk pathway liberates cytoplasmic
NF-κB/RelA from NFκB2 complexes in response to
IKKα∙NIK. Our experiments using various doses of the
allosteric IKK inhibitor indicate that expression of the
core EMT genes is significantly inhibited at very low
concentrations of BMS-345541. At this 1 μM concentra-
tion, BMS is relatively selective for IKK, over that of
other related MAPKs [22]. This behavior, together with
our observations that RelA knockout cells are also de-
fective in TGFβ-induced SNAI1 and ZEB expression,
support our conclusion that the IKK-NFκB pathway is
required for type II EMT. More work will be required to
identify whether the NF-κB pathway activated by TGFβ
is via the canonical, noncanonical or a combination of
the two pathways.
EMT induced alterations in the TNF signaling program
Our earlier genome-wide microarray studies discovered
that tonic cellular stimulation by TNF produces sequential
waves of NF-κB-dependent gene expression, with each
wave controlling distinct biological functions [58, 59]. The
most rapidly inducible, “early” genes were a group encod-
ing cytokines, important in paracrine signaling, whereas
late genes were those involved in antigen processing and
cell surface presentation of MHCI complexes [56]. Mech-
anistically, the early genes are under canonical pathway
control, and the late genes by noncanonical pathways [55,
56]. Recently we observed that that the EMT state pro-
duces both profound accentuation of early gene expres-
sion and changes in canonical-noncanonical pathway
coupling resulting in shortening the coupling interval be-
tween them [5, 58]. Although the mechanisms are still
under investigation, part of this effect was through tran-
scriptional reprogramming of NFκB-dependent pro-
moters, including that of TRAF1 and NFκB2 [5, 58].
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In this study we observe that the EMT state markedly
changes the TNF program in unexpected ways. Although
a cluster of early and late genes (Clusters E, C, respect-
ively Fig. 6b) are potentiated by EMT, our data suggest
that this is not a uniform behavior. Interestingly, large
subgroups of early and late genes (Clusters A, D, Fig. 6b)
are largely silenced in the EMT state. Conversely, a large
cluster of genes are activated in a late gene expression
pattern in mesenchymal cells that is not activated in
normal epithelial cells (Cluster F, Fig. 6b). Pathway ana-
lysis shows that the TNF program in normal hSAECs is
coupled to interferon signaling and innate immunity. By
contrast, the TNF program is re-routed by Type II EMT
to elicit the integrin signaling program, an essential
pathway controlling maintenance of EMT [59].
How might the TNF signaling pathway be affected so
dramatically by EMT? One explanation for this complex
behavior is through contextual effects of NF-κB associ-
ated modulators. In a recent study, we conducted a
probabilistic inference of modulator activity on RelA ac-
tivity using experimentally determined protein-protein
interactions integrated with ChIP-Seq and a compen-
dium of microarray data. The action identified 8349
modulator-RelA-target gene triplets, whose target genes
were regulated in six distinct expression modes [35].
Using this approach, a preliminary inference of EMT-
regulated NF-κB/RelA modulators identified FOXP1, a
tumor suppressor gene involved in cardiac development;
FN1 and CCDC80, interacting gene involved in extracel-
lular matrix formation; ACTN1, a gene important in for-
mation of actin polymers; and DOCK10, a Rho GTPase
associated with cytoskeletal motility, as key modulators
of the NF-κB pathway in EMT [61]. These functions
may suggest how the EMT state may modulate the activ-
ity of the ubiquitous NF-κB/RelA in a cell-state
dependent manner. More investigation will be required
to determine the effect of EMT on the expression of
RelA modulators. Moreover, these data suggest that the
biological consequences of activating the TNF program
are distinct in the normal vs EMT state.
Differences in Type II vs III EMT gene expression
programs
TGFβ-induced Type II EMT leads to disruption of mu-
cosal barrier function by inducing the loss of apical po-
larity, reduced epithelial cadherin and disruption of
epithelial adherens junctions [6], express α-SMA stress
fibers and intermediate filament VIM, to produce ECM
through secretion of Col1A and FN1, and to increase ex-
pression of MMPs to promote airway remodeling. This
cellular biology is a distinct biological phenomenon from
that of Type III induced in a primary transformed cell
background, associated with acquisition of motility and
resistance to chemotherapeutics.
Conclusions
Analysis of the gene program triggered by TGFβ has led
to a new understanding of the Type II EMT process.
First, we have identified a core set of TNF-inducible
genes enriched in experimentally determined NF-κB/
RelA binding sites. Second, we demonstrate that activa-
tion of NF-κB/RelA is required for initiation of TGFβ-
induced core EMT TFs and mesenchymal genes. Third,
we provide evidence that the gene program induced by
EMT in normal epithelial cells confers distinct biological
properties than that induced in mesenchymal cells.
Finally, we demonstrate that the evolution of the TNF
pathway is distinct in the EMT state, altering innate im-
munity and reinforcing EMT via integrin αV signaling.
These data have implications for the effect of EMT on
airway mucosal response in chronic respiratory disease.
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